CIBMTR评分可预测接受清髓性或减低强度预处理的伴有活动性疾病的急性髓系白血病患者进行异基因移植后的生存情况：意大利骨髓移植协作组的一项回顾性分析 - Suppr

The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo.

作者信息

Todisco E, Ciceri F, Oldani E, Boschini C, Micò C, Vanlint M T, Donnini I, Patriarca F, Alessandrino P E, Bonifazi F, Arcese W, Barberi W, Marenco P, Terruzzi E, Cortelazzo S, Santarone S, Proia A, Corradini P, Tagliaferri E, Falcioni S, Irrera G, Dallanegra L, Castagna L, Santoro A, Camboni A, Sacchi N, Bosi A, Bacigalupo A, Rambaldi A

机构信息

Hematology and Bone Marrow Transplant Units of Humanitas Cancer Center, Rozzano, Italy.

出版信息

Leukemia. 2013 Oct;27(10):2086-91. doi: 10.1038/leu.2013.208. Epub 2013 Jul 9.

DOI:10.1038/leu.2013.208

PMID:23835862

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3806246/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71d5/3806246/c521478f5cb9/leu2013208f1.jpg

相似文献

The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo.

Leukemia. 2013 Oct;27(10):2086-91. doi: 10.1038/leu.2013.208. Epub 2013 Jul 9.

Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO).

Bone Marrow Transplant. 2017 Jul;52(7):955-961. doi: 10.1038/bmt.2016.325. Epub 2017 Jan 9.

BU/melphalan and auto-SCT in AML patients in first CR: a 'Gruppo Italiano Trapianto di Midollo Osseo (GITMO)' retrospective study.

Bone Marrow Transplant. 2010 Apr;45(4):640-6. doi: 10.1038/bmt.2009.235. Epub 2009 Oct 5.

Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study.

Haematologica. 2010 Mar;95(3):476-84. doi: 10.3324/haematol.2009.011429. Epub 2009 Nov 10.

The impact of histopathologic examination of graft-versus-host disease in the era of reduced-intensity conditioning regimen: a study from the Gruppo Italiano Trapianto di Midollo Osseo.

Hum Pathol. 2011 Feb;42(2):254-68. doi: 10.1016/j.humpath.2010.07.004. Epub 2010 Nov 24.

Hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria: long-term results of a retrospective study on behalf of the Gruppo Italiano Trapianto Midollo Osseo (GITMO).

Haematologica. 2010 Jun;95(6):983-8. doi: 10.3324/haematol.2009.017269. Epub 2009 Dec 8.

Allogeneic bone marrow transplantation in children with acute myelogenous leukemia in first remission. Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP) and the Gruppo Italiano per il Trapianto di Midollo Osseo (GITMO).

Bone Marrow Transplant. 1994 Jun;13(6):771-6.

Am J Hematol. 2018 Mar;93(3):416-423. doi: 10.1002/ajh.25004. Epub 2018 Jan 8.

Early deaths in children after BMT. Bone Marrow Transplantation Group of the Italian Association for Pediatric Hematology and Oncology (AIEOP) and Gruppo Italiano Trapianto di Midollo Osseo (GITMO).

Bone Marrow Transplant. 1992 Nov;10(5):419-23.

Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT.

Haematologica. 2016 Jun;101(6):773-80. doi: 10.3324/haematol.2015.138180. Epub 2016 Mar 11.

引用本文的文献

Prognostic factors for allogeneic haematopoietic cell transplantation outcomes in primary refractory acute myeloid leukaemia (2013-2022): A retrospective study by the adult acute myeloid leukaemia working group of the Japanese Society for Transplantation and Cellular Therapy.

Br J Haematol. 2025 Aug;207(2):484-497. doi: 10.1111/bjh.20208. Epub 2025 Jun 16.

Treosulfan-Versus Melphalan-Based Reduced Intensity Conditioning in HLA-Haploidentical Transplantation for Patients ≥ 50 Years with Advanced MDS/AML.

Cancers (Basel). 2024 Aug 16;16(16):2859. doi: 10.3390/cancers16162859.

CLAG combined with total body irradiation as intensive conditioning chemotherapy prior to allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia.

Ann Hematol. 2024 Jan;103(1):241-249. doi: 10.1007/s00277-023-05502-0. Epub 2023 Oct 17.

Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01.

Bone Marrow Transplant. 2022 Jun;57(6):949-958. doi: 10.1038/s41409-022-01626-5. Epub 2022 Apr 12.

Pre-transplant cytoreductive therapy can improve overall survival of patients with MDS-AML but not MDS-EB2 receiving HLA-matched sibling donor peripheral blood stem cell transplantation.

Am J Cancer Res. 2020 Apr 1;10(4):1218-1228. eCollection 2020.

Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).

J Hematol Oncol. 2019 Apr 25;12(1):44. doi: 10.1186/s13045-019-0727-4.

Psychiatric Care in Hematopoietic Stem Cell Transplantation.

Psychosomatics. 2019 May-Jun;60(3):227-237. doi: 10.1016/j.psym.2019.01.005. Epub 2019 Jan 19.

Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome.

Bone Marrow Transplant. 2019 Jun;54(6):839-848. doi: 10.1038/s41409-018-0344-9. Epub 2018 Sep 26.

Management of primary refractory acute myeloid leukemia in the era of targeted therapies.

Leuk Lymphoma. 2019 Mar;60(3):583-597. doi: 10.1080/10428194.2018.1504937. Epub 2018 Sep 20.

Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission.

Cancer. 2017 Jun 1;123(11):2025-2034. doi: 10.1002/cncr.30536. Epub 2017 Jan 24.

本文引用的文献

Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation.

Bone Marrow Transplant. 2013 Mar;48 Suppl 1:S1-37. doi: 10.1038/bmt.2012.282.

Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients.

Leukemia. 2012 Aug;26(8):1779-85. doi: 10.1038/leu.2012.55. Epub 2012 Mar 1.

Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia.

Leukemia. 2011 May;25(5):808-13. doi: 10.1038/leu.2011.13. Epub 2011 Feb 22.

Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure.

J Clin Oncol. 2010 Aug 10;28(23):3730-8. doi: 10.1200/JCO.2010.28.8852. Epub 2010 Jul 12.

Defining the intensity of conditioning regimens: working definitions.

Biol Blood Marrow Transplant. 2009 Dec;15(12):1628-33. doi: 10.1016/j.bbmt.2009.07.004. Epub 2009 Sep 1.

Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study.

Lancet Oncol. 2009 May;10(5):489-500. doi: 10.1016/S1470-2045(09)70074-9. Epub 2009 Apr 1.

Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research.

Biol Blood Marrow Transplant. 2009 Mar;15(3):367-9. doi: 10.1016/j.bbmt.2008.12.497.

Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?

Best Pract Res Clin Haematol. 2007 Mar;20(1):29-37. doi: 10.1016/j.beha.2006.10.006.

The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison.

Leukemia. 2005 Jun;19(6):916-20. doi: 10.1038/sj.leu.2403770.

Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation.

Biol Blood Marrow Transplant. 2005 Feb;11(2):108-14. doi: 10.1016/j.bbmt.2004.10.008.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo.

作者信息

机构信息

Hematology and Bone Marrow Transplant Units of Humanitas Cancer Center, Rozzano, Italy.

出版信息

Leukemia. 2013 Oct;27(10):2086-91. doi: 10.1038/leu.2013.208. Epub 2013 Jul 9.

DOI:10.1038/leu.2013.208

PMID:23835862

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3806246/

Abstract

摘要

The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献